Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant CE-marks aortoiliac graft:

This article was originally published in Clinica

Executive Summary

Guidant has gained the go-ahead to market in Europe its Ancure Aortoiliac Endograft device as a less invasive treatment for those patients with abdominal aortic aneurysms (AAA), who are ineligible for Guidant's current endovascular graft due to advanced vascular disease in the iliac arteries. The product comprises a polyester graft or tube that is inserted through an incision in the groin and attached to the aorta with tiny metal hooks. This reinforces the aorta wall. The Indianapolis, Indiana firm plans to introduce the latest product in its line of aortic grafting devices in the US this year, pending FDA approval.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel